This article is a US government work and, as such, is in the public domain in the United States of America.
Development of a steroidogenic factor 1/Cre transgenic mouse line†
Article first published online: 11 AUG 2006
Published 2006 Wiley-Liss, Inc.
Volume 44, Issue 9, pages 419–424, September 2006
How to Cite
Bingham, N. C., Verma-Kurvari, S., Parada, L. F. and Parker, K. L. (2006), Development of a steroidogenic factor 1/Cre transgenic mouse line. Genesis, 44: 419–424. doi: 10.1002/dvg.20231
- Issue published online: 1 SEP 2006
- Article first published online: 11 AUG 2006
- Manuscript Accepted: 2 JUL 2006
- Manuscript Revised: 28 JUN 2006
- Manuscript Received: 11 MAY 2006
- National Institutes of Health (NIH). Grant Numbers: DK054480, R37NS33199
- National Institute of Neurological Disorders and Strokes (NINDS)
- National Institute of Mental Health (NIMH)
- steroidogenic factor 1;
The Cre-loxP strategy provides an approach to disrupt genes in specific tissues and/or cell types, circumventing lethality associated with global knockouts or secondary effects due to gene inactivation at other sites. A critical component is the development of transgenes that target Cre expression to specific cell types. Here, we describe the use of bacterial artificial chromosome (BAC) transgenesis to target Cre expression to tissues that express steroidogenic factor 1 (SF-1, officially designated Nr5a1). Consistent with the SF-1 expression pattern, the SF-1 BAC directed Cre expression to the somatic cells of the gonads, the adrenal cortex, the anterior pituitary, the spleen, and the ventromedial hypothalamic nucleus. This transgene provides a powerful tool to inactivate genes of interest in these tissues. genesis 44:419–424, 2006. Published 2006 Wiley-Liss, Inc.